Empagliflozin Improves Heart Failure with rEF in Nondiabetic patients: Study
In patients with type 2 diabetes, sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce the risk of hospitalization for heart failure by 30% to 35% and improve cardiac outcomes. In a recent study, researchers have found Empagliflozin an SGLP2i potentially improves cardiac outcomes and quality of life among nondiabetic patients with heart failure with reduced ejection fraction (HFrEF)....
In patients with type 2 diabetes, sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce the risk of hospitalization for heart failure by 30% to 35% and improve cardiac outcomes. In a recent study, researchers have found Empagliflozin an SGLP2i potentially improves cardiac outcomes and quality of life among nondiabetic patients with heart failure with reduced ejection fraction (HFrEF). The study findings were published in the Journal of the American College of Cardiology on January 19, 2021.
Previous clinical trial such as DAPA-HF trial and EMPEROR-Reduced trial have explained the heart failure benefits of SGLT2i to the realm of patients with heart failure with reduced ejection fraction (HFrEF). Of the utmost importance, these benefits in outcomes occur both in diabetic and nondiabetic patients. Researchers of the Mount Sinai hospital, New York hypothesized that SGLT2i would mitigate adverse left ventricular (LV) remodelling independently of diabetic status, which could explain their benefits in heart failure. Based on this hypothesis, they conducted a preclinical study, using a porcine model of heart failure which showed promising results. Therefore, they conducted EMPA-TROPISM (Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity) trial and assessed the effect of empagliflozin on LV function and volumes, functional capacity, and quality of life (QoL) in nondiabetic HFrEF patients.
It was a single-site, double-blind, randomized placebo-controlled trial in 84 nondiabetic HFrEF patients. Researchers randomly assigned the patients to receive either empagliflozin 10 mg daily or placebo for 6 months. The major outcome assessed was the change in LV end-diastolic and -systolic volume evaluated by cardiac magnetic resonance. Researchers also assessed the changes in LV mass, LV ejection fraction, peak oxygen consumption in the cardiopulmonary exercise test, 6-min walk test, and quality of life.
Key findings of the study were:
• On comparing empagliflozin with placebo, researchers have found that the empagliflozin was associated with a significant reduction of LV end-diastolic volume (−25.1 ± 26.0 ml) when compared with placebo (−1.5 ± 25.4 ml).
• They also found a reduction in LV end-systolic volume (−26.6 ± 20.5 ml vs −0.5 ± 21.9 ml for empagliflozin vs Placebo).
• They observed empagliflozin was associated with reductions in LV mass (−17.8 ± 31.9 g vs 4.1 ± 13.4 g) and LV sphericity, and improvements in LV ejection fraction (6.0 ± 4.2 vs −0.1 ± 3.9).
• They also noted that the empagliflozin was associated with improvements in peak oxygen consumption, oxygen uptake efficiency slope as well as in 6-min walk test and quality of life.
The authors concluded, "Empagliflozin administration to nondiabetic HFrEF patients significantly improves LV volumes, LV mass, LV systolic function, functional capacity, and quality of life when compared with placebo. Our observations strongly support a role for sodium-glucose cotransporter 2 inhibitors in the treatment of HFrEF patients independently of their glycemic status".
For further information:
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd